Cc1c(Cl)c2cc(N)ccc2n1C.Cc1nn(-c2ccnc(Cl)n2)cc1CN1CC(O)C1>C1COCCO1.CC(=O)O.CC(=O)O.CC(C)c1cc(C(C)C)c(-c2ccccc2P(C2CCCCC2)C2CCCCC2)c(C(C)C)c1.O=C([O-])[O-].[K+].[K+].[Pd]>Cc1nn(-c2ccnc(Nc3ccc4c(c3)c(Cl)c(C)n4C)n2)cc1CN1CC(O)C1A 40 mL scintillation vial charged with 3-chloro-1,2-dimethyl-1H-indol-5-amine (53.6 mg, 0.28 mmol), 1-((1-(2-chloropyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)azetidin-3-ol (70mg, 0.25 mmol), palladium(II) acetate (2.81 mg, 0.01 mmol), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (x--phos) (11.93 mg, 0.03 mmol) and Dioxane (3 mL) After being degassed by nitrogen bubbling , the reaction mixture was heated to 100 °C for 5 hours. LCMS analysis indicated no desired product and chloropyrimidine starting material was decomposed. The reaction mixture was discarded. Need to reverse the sequence.
Loading…
